HAEMALOGIX
Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.HaemaLogiX acquired the business and assets of Immune System Therapeutics Ltd and is embarking on a program of several inter-related projects that will validate antigen targets and products. Two novel drug targets - Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA), have been identified on the surface of human blood cancer and autoimmune cells. These targets are highly specific... to abnormal B-cells and have been identified in blood cancers such as multiple myeloma (MM), lymphoma and Waldenstroms macroglobulinemia. Our program will rationally review and pursue opportunities that will deliver a positive proof of the clinical and financial viability of our assets. These opportunities include: validation of antibodies and CAR-T cells; proof of concept for both Kappa and Lambda antigens; and a good understanding of their clinical utility in treating the selected patient populations In pursuing these projects we wish to deliver significant and risk mitigated medium term returns to our investors.
HAEMALOGIX
Industry:
Biotechnology Health Care Life Science Medical
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.haemalogix.com
Total Employee:
1+
Status:
Active
Contact:
+61292094444
Total Funding:
10 M AUD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online GStatic Google Static Content Sectigo SSL Sectigo Domain SSL
Similar Organizations
Arctic Vision
Arctic Vision is focused on the development and commercialization of innovative ophthalmology therapies.
iRepertoire
iRepertoire is to develop and commercialize immune repertoire sequencing technology and products.
myNEO
myNEO engages in the research, development, and optimization of the clinical exploitability of personalized cancer immunotherapy.
MYOR
MYOR uses skin-surface noninvasive monitoring technologies to adjust nutrition and enable health.
Pharmaceutical Biotechnology
Pharmaceutical Biotechnology focuses on the development and implementation of new biotech projects with high market potential.
Proteona
Proteona develops a genomic and proteomic analysis platform designed for immuno-oncology and immune profiling applications.
Reset Pharmaceuticals
Reset Pharma is a biotechnology company that focuses on the development and commercialization of novel psychedelic treatments.
ScalmiBio
ScalmiBio minimizes side-effects of oncology and immuno-oncology antibody therapeutics.
Senseonics
Senseonics is a medical device startup company that focuses on the design, development, and commercialization of glucose monitoring systems.
Current Employees Featured
Founder
Investors List
Platinum Asset Management
Platinum Asset Management investment in Venture Round - Haemalogix
Official Site Inspections
http://www.haemalogix.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Haemalogix"
Haemalogix - Crunchbase Company Profile & Funding
Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.HaemaLogiX acquired the business and assets of Immune System …See details»
Team | HaemaLogiX
HaemaLogiX was formed as a private Australian biotech company in late 2014. Soon after, we acquired the core proprietary technologies that are the foci of our research and development …See details»
Contact | HaemaLogiX
HaemaLogiX Ltd. Suite 306, Level 3, 343 George Street SYDNEY NSW 2000. Australia. Contact Us. HaemaLogiX Ltd. Suite 306, Level 3, 343 George Street SYDNEY NSW 2000. Australia. in. Team. Technology. Publications. …See details»
HaemaLogiX Company Profile 2024: Valuation, Funding …
HaemaLogiX General Information Description. Developer of a novel immuno-oncology and immune therapies designed for the treatment of hematologic malignancies and auto-immune diseases. The company is focused on the …See details»
Haemalogix - Contacts, Employees, Board Members, …
Haemalogix has 5 current employee profiles, including Co-Founder & Board Member Alan Liddle. Alan Liddle Co-Founder & Board Member Damian Clarke-Bruce Managing Director & Chief Executive OfficerSee details»
HaemaLogiX Announces Appointment of Damian Clarke-Bruce as …
SYDNEY, Nov. 13, 2023 /CNW/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, …See details»
Haemalogix - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Sep 8, 2021: Venture Round - …See details»
HaemaLogiX Names Damian Clarke-Bruce as CEO and MD
Nov 14, 2023 The HaemaLogiX team has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing and commercialisation. The …See details»
HaemaLogiX raises $10 million to advance multiple myeloma …
Sep 8, 2021 HaemaLogiX completes a fully subscribed $10 million share placement and welcomes Platinum Asset Management as core new institutional investor within its Platinum …See details»
HaemaLogiX is a small Australian-based biotech developing …
But ultimately as a company HaemaLogiX is a little organization. It is not going to be able to commercialize this technology globally ourselves, but the ultimate commercialization could …See details»
Platinum leads immuno-oncology company HaemaLogiX’s $10m …
Sep 9, 2021 Blood cancer immuno-oncology comapny HaemaLogiX is the latest to raise capital, bringing on Platinum Asset Management as its new cornerstone investor in a $10 million round.See details»
HaemaLogiX and Peter MacCallum Cancer Centre Announce
Jul 25, 2023 HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX's CAR-T cell …See details»
HaemaLogiX raises $10 million to advance multiple myeloma …
Sep 9, 2021 HaemaLogiX completes a fully subscribed $10 million share placement and welcomes Platinum Asset Management as core new institutional investor within its Platinum …See details»
HaemaLogiX - YouTube
HaemaLogiX is a clinical stage Australian biotech developing immunotherapies for blood cancers, with an initial focus on multiple myeloma. We’re developing monoclonal antibodies, CAR-T cell ...See details»
HaemaLogiX raises $10 million to advance multiple myeloma …
Sep 8, 2021 HaemaLogiX Pty Ltd +61 481 344 140. [email protected]. Media: Jane Lowe, Managing Director. IR Department +61 411 117 774. [email protected] . …See details»
Biotech HaemaLogiX plots 2025 IPO, ramps up blood cancer trials
Biotech HaemaLogiX plots 2025 IPO, ramps up blood cancer trials. HaemaLogiX, which counts former minister Greg Hunt as a director, is readying to float in 2025, as it seeks inroads into …See details»
HaemaLogiX raises $10 million to advance multiple myeloma
Sep 8, 2021 HaemaLogiX completes a fully subscribed $10 million share placement and welcomes Platinum Asset Management as core new institutional investor within its Platinum …See details»
News (All) - Haemalogix
Jan 31, 2024 HaemaLogiX's CMDO, Tertia Dex to speak at the Women in BIO and Health – Industry and Networking Forum. 5 May 2024. Read More. 28 February 2024. Honouring Rare …See details»
Technology - Haemalogix
HaemaLogiX has discovered two antigens that are found on the cell surface of cancer cells in patients with myeloma and AL amyloidosis, on some lymphoma and Waldenstrom’s …See details»